Thermo Fisher Scientific Inc
TMO · NYSE
TMO · NYSE
Thermo Fisher sells scientific instruments, laboratory supplies, diagnostic tests, and services to pharmaceutical and biotechnology companies, hospitals, clinical laboratories, universities, government agencies, and other research organizations. Its businesses span Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. It earns revenue from equipment and instrument sales, recurring consumables and reagents, diagnostic products, and services including drug development and manufacturing. The supplied information does not state the segments’ individual revenue contributions. In FY2025, the company reported $44.6 billion of revenue and $6.7 billion of net income, up from $42.9 billion and $6.3 billion, respectively, in FY2024.
Thermo Fisher rose 4.82%, from $676.54 on Oct. 22 to $709.18 on Oct. 29. After slipping to $673.82 on Oct. 23, the shares advanced each trading day from Monday through Thursday, with no material reversal. The clearest company-specific context in the supplied evidence was two analyst target increases announced Oct. 23: Citi raised its target to $800 from $685, and Argus Research raised its target to $780 from $560 while maintaining Buy. Those changes preceded the week’s advance, but the evidence does not establish that they caused it. No company operating announcement or broader market data was supplied to explain the move further.
Thermo Fisher rose 2.59% over the supplied period, from $662.24 on October 12 to $679.38 on October 19. The main catalyst was its third-quarter report, which coverage described as beating earnings and revenue estimates, with higher revenue and earnings and improving margins. Shares climbed from $663.04 on October 13 to $696.49 on October 15, including a 3.46% rise on October 15. The advance then reversed: the stock fell to $690.00 on October 16 and $679.38 on October 19, giving back much of the post-results rally. Headlines also described an earnings disconnect and a premarket decline despite the beat, pointing to a less uniformly positive market response than the headline results suggested.
Thermo Fisher fell $14.52, or 2.15%, over the reported interval, from $676.76 on October 5 to $662.24 on October 12. The largest move came on Tuesday, October 6, when the shares dropped to $656.58; they recovered to $662.06 on Wednesday, slid again to $651.98 on Thursday, then partially rebounded on Friday and Monday. The supplied evidence does not identify a company-specific announcement or explain the declines and recoveries. It therefore supports describing the week as a volatile pullback without a documented company catalyst, but provides no market or sector performance data with which to attribute the move to broader conditions.
TMO fell $23.03, or 3.39%, over the supplied Sep. 29–Oct. 6 closing window, from $679.61 to $656.58. The path was volatile: shares slipped to $675.05 on Sep. 30, then dropped sharply to $652.51 on Oct. 1; they recovered modestly to $654.80 on Oct. 2 before surging to $676.76 on Oct. 5. That rebound was almost entirely reversed the next session, when TMO fell to $656.58 on Oct. 6, the period’s highest-volume session at 2.75 million shares. The supplied evidence identifies no company-specific catalyst for the swings and provides no market-index or sector performance with which to attribute the decline to broader trading.
Thermo Fisher fell $25.88, or 3.81%, from $678.39 to $652.51 over the reported interval. It rose to $679.61 by Tuesday, then slipped on Wednesday and dropped $22.54 on Thursday, giving back the early-week gains. The supplied evidence does not identify a company-specific catalyst for that Thursday decline or establish a market-wide cause. Company-related items in the feed included Biodesix’s developing tumor-informed and tumor-naive MRD test programs with Thermo Fisher and Bio-Rad, but no deal value, launch date, or financial impact was reported. A reported $614.7 million inflow into the XLV healthcare ETF was a supportive sector-flow signal, not evidence of buying specifically in TMO; the share price nevertheless fell.
TMO rose 2.60%, from $648.43 to $665.30, over the reported window. The stock gained $9.89 on September 17, fell $6.87 on September 18, then advanced on September 21 and 23, with a slight dip on September 22, to finish at the window high. The supplied evidence does not establish a dated company-specific catalyst for those moves: coverage refers to new CHO K1 media products, but gives no timing that connects the launches to trading. Nor does it provide market or sector performance for comparison, so the broader context cannot be identified. The move was positive overall, with a brief reversal after the September 17 gain.
Thermo Fisher Scientific fell 2.28%, from $617.10 to $603.02, after a volatile week in which it dropped 2.7% on September 1, recovered through September 3 to close at $618.43, then reversed lower on September 4 and September 8. The largest decline came on September 8, when volume rose to 2.70 million shares, but the supplied evidence identifies no company-specific announcement, earnings release, guidance change, or analyst action during the period to explain the reversal. The stock therefore moved without a documented company-specific catalyst in the supplied material. The week’s pattern was instead a sharp early selloff, a near-complete recovery, and a material late-week giveback.
TMO fell 1.95%, from $630.70 to $618.43, as selling intensified through Tuesday before a material rebound over the final two sessions. The stock declined from $617.10 on Monday to $600.50 on Tuesday, then recovered to $608.54 Wednesday and $618.43 Thursday, giving back much of the early-week loss. Company-specific items were mixed: Zacks highlighted the launch of Thermo Fisher’s EMPAD G2 detector as a potential positive for Analytical Instruments, while BNK Invest flagged ETF share outflows involving TMO. Recent CEO, COO and other executive share transactions also appeared in the news, but the evidence does not establish them as a trading catalyst. No company-specific event clearly explains the weekly decline, which also reflected broader market positioning.
Thermo Fisher fell $7.09, or 1.13%, from $629.27 on August 21 to $622.18 on August 28. Trading was initially stable, with small declines on Monday and Tuesday, before the stock gained 0.89% on Wednesday. It then gave back part of that advance Thursday and lost 1.35% Friday, closing at the weekly low on lighter volume. The supplied evidence does not identify company-specific operating news that explains the reversal. Coverage instead highlighted an ETF outflow involving the iShares Russell 1000 Value ETF and reports of Thermo Fisher insider selling, including an officer transaction valued at $12.56 million, but it does not establish that either event drove the week. The move therefore appears primarily market- or flow-related.
TMO rose 4.47% over the week, from $574.03 to $599.69. Trading was volatile: shares fell 1.6% on Monday, dropped another 1.6% on Tuesday to $564.75, then recovered across the remainder of the period, including a 2.4% gain on Friday and a further 1.0% rise on Monday, August 10. The supplied evidence does not identify a single company-specific catalyst for the advance. Positive signals included reports that India is one of Thermo Fisher’s fastest-growing markets and fund additions by Dodge & Cox and Magellan Asset Management. Those signals were partly offset by disclosed selling by CEO Marc Casper and executives, while other asset managers reduced positions. No broader market driver is supplied.
Thermo Fisher shares fell $11.66, or 2.02%, from $576.41 to $564.75 over the supplied week. The stock was essentially flat through July 30, edging up to $576.77, then weakened to $574.30 on July 31 and slipped again on August 3 before dropping 1.62% on August 4. The supplied evidence does not identify a dated company-specific trading catalyst for the decline. It does highlight a favorable backdrop—Thermo Fisher raised its 2026 outlook after strong second-quarter results, citing demand, acquisitions and margin gains—but does not establish that this news drove the week’s price action. No broader-market or sector performance context was provided.
